At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 155 target
Drug / intervention
NB1011drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase
In Brief
A Phase 2 clinical trial evaluating NB1011 for Tumors. Completed, enrolled 155 participants across 3 sites in 2 countries.
Detailed Summary
The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTumors
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2005
First PostedNov 2005
Primary CompletionDec 2007
TodayJul 2026
First PostedNov 4, 2005
Enrollment StartSep 1, 2005
Primary CompletionDec 12, 2007
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.7 years ago
Interventions
NB1011drug